CYTOKINETICS INC
CYTK · XNASCIK 1061983fmd_0P2ZX7VF8MH4BH81K3Q86Z6KK9Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 1999 to Sep 30, 2026, 77 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 106 | 13 | 32 | 27 | 56 | 70 | 95 | 8 | 18 | 88 |
| Realized investment gains (losses) | – | – | – | – | – | – | (0) | (0) | 0 | 0 |
| Research and development | 60 | 90 | 89 | 86 | 97 | 160 | 241 | 330 | 339 | 416 |
| Total operating expenses | 88 | 127 | 120 | 126 | 150 | 257 | 419 | 504 | 555 | 700 |
| Operating income | 19 | (113) | (89) | (99) | (94) | (186) | (324) | (496) | (536) | (612) |
| Interest expense | 3 | 3 | 4 | 7 | 16 | 16 | 19 | 28 | 38 | 46 |
| Interest and investment income | 0 | – | 4 | 5 | 5 | 1 | 11 | – | – | – |
| Other non-operating income (expense) | 0 | 3 | 4 | 5 | 5 | 0 | 11 | 28 | 52 | 48 |
| Income before taxes | 16 | (128) | (106) | – | – | – | – | – | – | – |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | 16 | (128) | (106) | – | – | – | – | – | – | – |
| Net income | 16 | (128) | (106) | (122) | (127) | (215) | (389) | (526) | (590) | (785) |
| Net income to common shareholders | – | – | – | – | – | – | – | – | – | – |